Characteristics of survivors of HL and community controls
| . | Survivors N = 204 . | Controls N = 205 . | P value . |
|---|---|---|---|
| n (%) . | n (%) . | ||
| Sex | |||
| Male | 97 (47.5) | 99 (48.3) | 0.88 |
| Female | 107 (52.5) | 106 (51.7) | |
| Race | |||
| White | 172 (84.3) | 176 (85.9) | 0.66 |
| Other | 32 (15.7) | 29 (14.1) | |
| Smoking Status | |||
| Current | 39 (19.1) | 29 (14.3) | 0.37 |
| Former | 35 (17.2) | 41 (20.2) | |
| Never | 130 (63.7) | 133 (65.5) | |
| Body mass index | |||
| Underweight | 7 (3.4) | 3 (1.5) | 0.23 |
| Normal weight | 51 (25.0) | 62 (30.2) | |
| Overweight | 73 (35.8) | 60 (29.3) | |
| Obese | 73 (35.8) | 80 (39.0) | |
| Age at assessment (y) | Mean (SD) | ||
| 36.6 (8.01) | 36.7 (9.17) | 0.84 | |
| Median (min-max) | |||
| Age at diagnosis (y) | 14.7 (3.0-22.6) | ||
| Time since diagnosis (y) | 20.6 (10.7-45.6) | ||
| Anthracyclines (n = 156) mg/m2 | 157.2 (91.0-400.0)∗ | ||
| IV methotrexate (n = 85) mg/m2 | 123.2 (20.3-167.7) | ||
| Bleomycin (n = 58) mg/m2 | 35.6 (5.0-95.0) | ||
| Corticosteroids (n = 140) mg/m2 | 2240 (250-4480) | ||
| Vincristine (n=182) mg/m2 | 45.9 (9.2-151.2) | ||
| Cyclophosphamides (n=113) mg/m2 | 3655 (1332-22 889)† | ||
| Chest Radiation (n=204) Gy | 26.0 (15.0-45.0) | ||
| Neck Radiation (n=204) Gy | 26.0 (15.0-51.0) | ||
| N (%) | |||
| Relapsed | 14 (6.9) | ||
| Diagnosed with second malignancy | 48 (24.0) |
| . | Survivors N = 204 . | Controls N = 205 . | P value . |
|---|---|---|---|
| n (%) . | n (%) . | ||
| Sex | |||
| Male | 97 (47.5) | 99 (48.3) | 0.88 |
| Female | 107 (52.5) | 106 (51.7) | |
| Race | |||
| White | 172 (84.3) | 176 (85.9) | 0.66 |
| Other | 32 (15.7) | 29 (14.1) | |
| Smoking Status | |||
| Current | 39 (19.1) | 29 (14.3) | 0.37 |
| Former | 35 (17.2) | 41 (20.2) | |
| Never | 130 (63.7) | 133 (65.5) | |
| Body mass index | |||
| Underweight | 7 (3.4) | 3 (1.5) | 0.23 |
| Normal weight | 51 (25.0) | 62 (30.2) | |
| Overweight | 73 (35.8) | 60 (29.3) | |
| Obese | 73 (35.8) | 80 (39.0) | |
| Age at assessment (y) | Mean (SD) | ||
| 36.6 (8.01) | 36.7 (9.17) | 0.84 | |
| Median (min-max) | |||
| Age at diagnosis (y) | 14.7 (3.0-22.6) | ||
| Time since diagnosis (y) | 20.6 (10.7-45.6) | ||
| Anthracyclines (n = 156) mg/m2 | 157.2 (91.0-400.0)∗ | ||
| IV methotrexate (n = 85) mg/m2 | 123.2 (20.3-167.7) | ||
| Bleomycin (n = 58) mg/m2 | 35.6 (5.0-95.0) | ||
| Corticosteroids (n = 140) mg/m2 | 2240 (250-4480) | ||
| Vincristine (n=182) mg/m2 | 45.9 (9.2-151.2) | ||
| Cyclophosphamides (n=113) mg/m2 | 3655 (1332-22 889)† | ||
| Chest Radiation (n=204) Gy | 26.0 (15.0-45.0) | ||
| Neck Radiation (n=204) Gy | 26.0 (15.0-51.0) | ||
| N (%) | |||
| Relapsed | 14 (6.9) | ||
| Diagnosed with second malignancy | 48 (24.0) |